Kremers Urban Pharmaceuticals: Solving Your Toughest Problems

Generic SupplementsGeneric Supplement 2013

Getting pharmaceutical products to market is hard enough. Challenges regarding active pharmaceutical ingredient (API), formulation, drug delivery technologies, and manufacturing can make the task seem even more insurmountable. KREMERS URBAN Pharmaceuticals is a company that delivers the product solutions and dedicated customer service needed to get specialty generic products to market without all the perplexity.

Providing Leadership Through the Drug Development Maze

Many promising drugs are abandoned early because of difficult-to-synthesize ingredients, complicated formulations, manufacturing issues, or legal challenges. KREMERS URBAN Pharmaceuticals, a subsidiary of Belgium-based UCB, strives to deliver the tough solutions and reliable service that get products to market. The company’s focus is providing a wide array of generic pharmaceuticals - particularly products with difficult-to-produce or limited-supply APIs or finished goods formulations, dedicated containment facilities, or Paragraph IV challenges - and biosimilar products. It is a strategy that is achieved through a combination of internal development and strategic partnerships.

The vision of KREMERS URBAN is to be a premier specialty generic pharmaceutical company with a portfolio of high-barrier-to-entry products and limited competition. Leveraging the vast resources of its parent company, KREMERS URBAN is moving to the forefront of delivering the tough solutions necessary to get complex products into the market. Its professionals are experts at increasing efficiencies and reducing the cost of getting generic products to the appropriate market segments.

The newest products in the KREMERS URBAN portfolio are Atorvastatin Calcium Tablets and Tacrolimus Capsules, USP. KREMERS URBAN extended-release products that require complex drug development technology and manufacturing process include Hydrocodone Polistirex and Chlorpheniramine Polistirex Pennkinetic® Extended-Release Suspension CIII (authorized generic for Tussionex® Pennkinetic® Extended-Release Suspension CIII), Isosorbide Mononitrate Extended-Release Tablets, Methylphenidate HCI Extended-Release Capsules CD CII (authorized generic for Metadate CD® CII), Nifedipine Extended-Release Tablets USP, Omeprazole Delayed-Release Capsules, Oxybutynin Chloride Extended-Release Tablets USP, Pantoprazole Sodium Delayed-Release Tablets, Verapamil Hydrochloride Extended-Release capsules, and transdermal generic products. The company stands behind each of its products, ensuring the highest standards available.

In addition to aggressively pursuing in-licensing generic drug products and internal research and development, KREMERS URBAN looks to expand its generic product portfolio by leveraging the biopharmaceutical capabilities being developed by UCB. KREMERS URBAN also seeks strategic alliances in the development of products and drug delivery technologies that would further enhance its capabilities or offerings.

Continuing to Exceed Customer Expectations

KREMERS URBAN has made impressive strides since it embarked on its own in 2006. The company has tripled manufacturing output and continues to excel in its service and capabilities. Fill rates, lead times, and service levels consistently attain 100%, meeting or exceeding all of its customers’ expectations. All this translates to major corporate growth and more extensive capabilities. Along with commercial offices in Princeton, New Jersey, a dedicated customer service headquarters is located in Seymour, Indiana, where KREMERS URBAN has also established an impressive 400,000-square-foot pharmaceutical manufacturing plant. With its dedicated facilities, comprehensive infrastructure, technical expertise, and UCB corporate support, KREMERS URBAN is uniquely structured and positioned to manage high barriers to entry.

Whether it is complex APIs, drug delivery systems, or challenging product formulations, you can trust the professionals at KREMERS URBAN to overcome the complications of market entry and SOLVE THE PUZZLE OF SPECIALTY GENERICS.

For more information, visit

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.